ABL1 and acute myeloid leukemia: In ELN 2017 favorable risk NPM1mut AML subgroup, molecular failure (defined as NPM1mut/ABL1 >0.05% after consolidation or NPM1mut reappearance after molecular response; which affected 40% of NPM1mut cases) served as indication for allogeneic HSCT in first complete remission.